Abstract 3813: Relationship between race/ethnicity and oncologic outcomes in patients with biochemical recurrence after primary treatment for prostate cancer
Authors: Khan Nasreen , Quintero Vanessa , Beck Clara , Dimova-Dobreva Miryana , Patel Binita 
Published: March 2024

Abstract
Background: Prostate cancer (PC) is the most common form of cancer in men and accounts for ~35% and 24% of all new cancer diagnoses in Black and Hispanic men, respectively. Incidence rates of PC are higher and cancer is diagnosed at a younger age in Black compared to White men. The most frequently utilized primary treatment options are radical prostatectomy (with or without adjuvant radiotherapy) or radiotherapy. Despite the success of primary treatments for localized PC, many patients (pts) will eventually develop biochemical recurrence (BCR), defined as rising prostate-specific antigen (PSA) levels. Pts with BCR are at a higher risk of developing distant metastases and ultimately dying from PC. This targeted literature review aimed to assess the real-world (RW) relationship between race/ethnicity and BCR, and further identify any differences in oncologic outcomes (risk of metastases, PC-specific mortality, and overall survival).
Methods: A targeted literature search was performed using Embase, PubMed, and the past 2 years of American Society of Clinical Oncology conference proceedings. Selected studies were limited to English-language articles focusing on BCR and race or ethnicity among US populations, published between 1/2010 and 7/2023.
Results: Ten studies were selected after title and abstract review. Most studies had a White pt majority (83%-92%). Six studies reported no differences in BCR or oncologic outcomes when pts were stratified by race/ethnicity. Four studies reported a higher BCR risk for Black pts with low-risk PC after radical prostatectomy, but not for pts with high-risk PC. PSA and PSA doubling time (PSADT) were found to be strong predictors of oncologic outcomes.
Conclusions: The FDA draft guidance on diversity plans recommends that clinical trials enroll an adequate number of participants from underrepresented racial and ethnic populations. This requires an understanding of the diversity of the population that will eventually use the treatment and of which race/ethnicity differences in outcomes should be expected and investigated. Based on this targeted review among pts with localized PC, most RW studies had a White pt majority, and the race distribution in these studies aligned with published census and epidemiology data. In addition, findings suggest that race/ethnicity differences were not pronounced among high-risk PC pts in the US when given equal access to care or treatment, and that oncologic outcomes and BCR risk were similar across Black, White, and Hispanic pt populations. Conversely, PSA and PSADT may be stronger prognostic markers for BCR and oncologic outcomes. Future clinical trials are needed to support these RW findings and should aim to actively enroll racial/ethnic minorities to identify potential differences in efficacy and safety, and to help advance the evidence base for pt PC management.
Citation Format: Nasreen Khan, Vanessa Quintero, Clara Beck, Miryana Dimova-Dobreva, Binita Patel. Relationship between race/ethnicity and oncologic outcomes in patients with biochemical recurrence after primary treatment for prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3813.